Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 20 Oct 2020
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.

Lorecivivint for knee OA unsuccessful in phase IIa trial

05 Oct 2020

The novel Wnt pathway modulator lorecivivint does not appear to be effective for treating pain and inhibiting structural progression in moderate-to-severe knee osteoarthritis (OA), according to the results of a phase IIa trial.

In total, 452 patients aged 40–80 years with Kellgren/Lawrence (K/L) radiographic disease stage 2 or stage 3 OA were randomized to receive a single 2‐ml intra-articular injection of lorecivivint at 0.03 mg (n=112), 0.07 mg (n=117), or 0.23 mg (n=109) or placebo (n=114).

Of the patients who completed the study, 103 (92 percent) were on lorecivivint 0.03 mg, 107 (91.5 percent) on 0.07 mg, 95 (86.4 percent) on 0.23 mg, and 97 (83.6 percent) were on placebo. Their mean age was 60.3 years and mean body mass index 29.9 kg/m2, while 58.9 percent of the population were women.

At week 13, all groups demonstrated clinically meaningful (≥20‐point) improvements from baseline in the primary endpoint of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score. The study drug did not produce significant improvements compared with placebo (mean change, −23.3 on 0.03 mg, −23.5 on 0.07 mg, −21.3 on 0.23 mg vs −22.1 on placebo; p>0.05 for all comparisons).

However, at week 52, lorecivivint 0.07 mg showed superiority over placebo in terms of WOMAC pain and function scores in the subgroups of patients with unilateral symptoms of knee OA (difference, −8.73; p=0.049 and difference, −10.26; p=0.036, respectively) and those with unilateral symptoms but without widespread pain (difference, −11.21; p=0.025 and difference, −13.38; p=0.017, respectively)

None of the treatment groups achieved a significant change in medial joint space width (JSW) at week 52 (mean change, −0.04 mm on 0.03 mg, −0.09 mm on 0.07 mg, −0.16 mm on 0.23 mg, and −0.14 mm on placebo).

The 0.07-mg lorecivivint dose likewise significantly improved medial JSW compared with placebo at week 52 among patients with unilateral symptoms of knee OA (difference, 0.39 mm; p=0.021) and those with unilateral symptoms but without widespread pain (difference, 0.42 mm; p=0.032).

Lorecivivint was safe and well tolerated.

The findings point to a target population in whom lorecivivint exerts potential efficacy, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 20 Oct 2020
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Yesterday
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.